FDA approves Shire's extended-release ADHD drug

09/3/2009 | Reuters

The FDA approved Shire's Intuniv, an extended-release drug for attention-deficit/hyperactivity disorder in children ages 6 to 17. The British company said the drug, the first selective alpha-2A receptor agonist for ADHD, is expected to be available at U.S. pharmacies in November.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ